Skip to main content
SpringerLink
Log in

Primary Endocrine Treatment of Advanced Prostate Cancer

  • Conference paper
Book cover Prostate Cancer 2000

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Clinical prostate cancer has been recognised as a single biological process with a usually slow but constant growth. This clinical progression can be temporarily arrested by endocrine treatment which offers palliation but will never cure patients with advanced prostatic cancer. Unfortunately, prostate cancer covers a wide range of disease where the biological potential of the tumour predicts prognosis overriding all forms of treatment at any disease stage. It is therefore crucial to incorporate the known and validated prognostic factors into clinical practice so that patients with good prognostic factors may receive the treatment least aggressive to their quality of life, which may even be no treatment, while patients with poor prognostic factors, where survival or the lowest probability of death from prostate cancer is the important endpoint, would be candidates for aggressive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Denis LJ: Controversies in the management of localised and metastatic prostatic cancer. Eur J Cancer 1991 (27):333–341

    Article  PubMed  CAS  Google Scholar 

  2. Hermanek P and Sobin LH: TNM Classification of Malignant Tumors, ed 4, rev 2. Springer Verlag, Berlin 1992.

    Google Scholar 

  3. Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson M, Sylvester R, Armitage TH and the EORTC Urological Group: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: A sub-analysis of EORTC trial 30853. Cancer 1990 (66):3–10

    Google Scholar 

  4. Denis L: Staging and prognosis of prostate cancer. Eur Urol 1993 (24):13–19

    PubMed  Google Scholar 

  5. Soloway MS, Hardeman SW, Hickey DP, Todd BB, Soloway SM, Moinuddin M, Memphis TN: Simple grading system for bone scans correlates with survival for patients with stage D2 prostatic cancer (abstract). J Urol 1987 (138):359

    Google Scholar 

  6. Cooper EH, Armitage TG, Robinson MRG, Newling DWW, Richards BR, Smith PH, Denis L and Sylvester R: Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990 (66):1025–1028

    PubMed  CAS  Google Scholar 

  7. Huggins C, Stevens RE and Hodges CV: Studies of prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surgery 1941 (43):209–228

    CAS  Google Scholar 

  8. Denis L and Mahler C: Prostatic cancer: An overview. Rev Oncol 1990 (3):665–677

    Google Scholar 

  9. Veterans Administrative Cooperative Urological Research Group: The effects of treatment on survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967 (124):1011–1017

    Google Scholar 

  10. Bailar JC and Byar DP: Estrogen treatment for cancer of the prostate: Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970 (26):257–261

    Article  PubMed  Google Scholar 

  11. Adolfsson J, Ronstrom L, Carstensten J, Lowhagen T and Hedlund PO: The natural course of low grade, non-metastatic prostate carcinoma. Br J Urol 1990 (65):611–614

    Article  PubMed  CAS  Google Scholar 

  12. Johansson J, Adams H and Anderson S: Natural history of localised prostatic cancer. Lancet 1989 (1):799–803

    Article  PubMed  CAS  Google Scholar 

  13. Denis LJ, Whelan P, Carneiro de Moura JL, Newling D, Bono A, De Pauw M, Sylvester R and Members of the EORTC GU Group and EORTC Data Center: Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 1993 (42):119–129

    Article  PubMed  CAS  Google Scholar 

  14. Cassileth BR, Soloway MS, Vogelzang NJ et al: Patients’ choice of treatment in stage D prostate cancer. Urology 1989 (33):57–62

    Article  PubMed  CAS  Google Scholar 

  15. Glenn JF: Subepididymal orchiectomy: The acceptable alternative. J Urol 1990 (144):942–944.

    PubMed  CAS  Google Scholar 

  16. Robinson MRG: Complete androgen blockade: The EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilbestrol in the treatment of metastatic carcinoma of the prostate. In: Murphy GP, Khoury S, Küss R, Chatelain C, Denis L (eds) Prostate Cancer Part A: Research, Endocrine Treatment and Histopathology. AR Liss, New York 1987, pp 383–390

    Google Scholar 

  17. Aro J: Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. The Prostate 1991 (18):131–137

    Article  PubMed  CAS  Google Scholar 

  18. Benson R and Hartley-Asp B: Mechanisms of action and clinical uses of estramustine. Cancer Investigation 1990 (8):375–380

    Article  PubMed  CAS  Google Scholar 

  19. Seidman AD, Scher HI, Petrylak D, Dershaw DD and Curley T: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992 (147):931–934

    PubMed  CAS  Google Scholar 

  20. Kaisary AV, Tyrrell CJ, Peeling WB and Griffiths K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991 (67):502–508

    Article  PubMed  CAS  Google Scholar 

  21. Citrin DL, Resnick MI, Guinan P, Al-Bussam N, Scott M, Gau TC and Kennealey GT: A comparison of Zoladex R and DES in the treatment of advanced prostate cancer: Results of a randomized multicenter trial. The Prostate 1991 (18):139–146

    Article  PubMed  CAS  Google Scholar 

  22. Schulze H and Senge T: Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990(144):934–941

    PubMed  CAS  Google Scholar 

  23. de Voogt HJ: The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. The Prostate 1992 (4):91–95

    Article  Google Scholar 

  24. Jansen JE: Prevention of hot flushes with cyproterone acetate (CPA). In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Recent Advances in Urological Cancers: Diagnosis and Treatment. FUS, Paris 1990, pp 70–71

    Google Scholar 

  25. Denis L and Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993 (72):3888–3895

    Article  PubMed  CAS  Google Scholar 

  26. Mahler C and Denis L: Clinical profile of a new non steroidal anti-androgen. J Steroid Biochem Mol Biol 1990(37):921–924

    Article  PubMed  CAS  Google Scholar 

  27. Neri R, Florance K, Koziol P and Van Cleave S: A biological profile of a non steroidal anti-androgen Sch 13521. Endocrinology 1972 (91):427–437

    Article  PubMed  CAS  Google Scholar 

  28. Sogani PC, Vagaiwala MR and Whitmore WF: Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984 (54):744–750

    Article  PubMed  CAS  Google Scholar 

  29. Prout GR, Keating MA, Griffin PP and Schiff SF: Long-term experience with flutamide in patients with prostatic carcinoma. Urology 1989 (34):37–45

    Article  PubMed  Google Scholar 

  30. Lund F and Rasmussen F: Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 1988 (61):140–142

    Article  PubMed  CAS  Google Scholar 

  31. Johansson JE, Lingärdh G, Andersson SO, Zador G and Beckman KW: Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 1987 (29):55–59

    Article  PubMed  CAS  Google Scholar 

  32. Furr BJA, Valcaccia B, Curry B, Woodburn JR, Chesterton G and Tucker H: ICI 176;334. A novel non steroidal peripherally selective anti-androgen. J Endocrinol 1987 (113):R7–R9

    Article  PubMed  CAS  Google Scholar 

  33. Tyrrell CJ: Casodex: A pure non-steroidal antiandrogen used as monotherapy in advanced prostate cancer. The Prostate 1992 (4):97–104

    Article  CAS  Google Scholar 

  34. Kaisary AV: Current clinical studies with a new, nonsteroidal antiandrogen Casodex (ICI 176,334). Clinical Developments in Prostate Cancer, 1993 (abstract). Satellite Symposium held at the 2nd International Congress of the Dutch Urological Association, Amsterdam, 3 November 1993

    Google Scholar 

  35. Bracci U: Anti-androgens in the treatment of prostatic cancer. Eur Urol 1979 (5):303–306

    PubMed  CAS  Google Scholar 

  36. Labrie F, Dupont A and Bélanger A: A complete androgen blockade for the treatment of prostate cancer. In: de Vita VTJr, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. JB Lippincott, Philadelphia 1985, pp 193–200

    Google Scholar 

  37. Denis L and Mettlin C: Conclusions from the American Cancer Society workshop on combined castration and androgen blockade therapy in prostate cancer, Atlanta, Georgia, September 18–20, 1989. Cancer 1990 (66):1086–1089

    PubMed  CAS  Google Scholar 

  38. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 (321):419–429

    Article  PubMed  CAS  Google Scholar 

  39. Kelly WK and Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993 (149):607–609

    PubMed  CAS  Google Scholar 

  40. Goldenberg S, Bruchovsky N, Rennie PS, Coppin CM and Brown EM: The use of synergistic hormonal combinations in the treatment of advanced prostatic cancer: cyproterone acetate plus mini-dose diethylstilbestrol. Proceedings of the International Symposium on Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)Steroidal Agents, 1986, June 4–6, Rotterdam, The Netherlands

    Google Scholar 

  41. Huben PR, Murphy GP and the Investigators of the National Prostatic Cancer Project: A comparison of diethylstilboestrol or orchiectomy with buserelin and with methotrexate plus diethylstilboestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1988 (62):1881–1887

    Article  PubMed  CAS  Google Scholar 

  42. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991 (145):907–923

    PubMed  CAS  Google Scholar 

  43. Schröder FH: What is new in endocrine therapy of prostatic cancer? In: Newling DWW, Jones WG (eds) Prostate Cancer and Testicular Cancer. Wiley-Liss Inc, New York 1990, pp 45–52

    Google Scholar 

  44. Fair WR, Aprikian A, Sogani P, Reuter V and Whitmore WF: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993 (71):1031–1038

    Article  PubMed  CAS  Google Scholar 

  45. Witjes WPJ, Horenblas S, Oosterhof GON, Schaafsma HE and Debruyne FMJ: Neoadjuvant therapy in prostate cancer — Is it of any use? Eur Urol 1993 (24):433–437

    PubMed  CAS  Google Scholar 

  46. Calais da Silva F, Reis E, Costa T, Denis L and Members of the Quality of Life Committee of the EORTC Genitourinary Group: Quality of life in patients with prostatic cancer. Cancer 1993 (71):1138–1142

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, A.Z. Middelheim and Vrije Universiteit Brussels, Lindendreef 1, 2020, Antwerp, Belgium

    Louis J. Denis

  2. Department of Endocrinology, A.Z. Middelheim and Vrije Universiteit Brussels, Lindendreef 1, 2020, Antwerp, Belgium

    Charles Mahler

Authors
  1. Louis J. Denis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Mahler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Algemeen Ziekenhuis Middelheim, Lindendreef 1, 2020, Antwerp, Belgium

    Louis Denis

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Denis, L.J., Mahler, C. (1994). Primary Endocrine Treatment of Advanced Prostate Cancer. In: Denis, L. (eds) Prostate Cancer 2000. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79178-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79178-9_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79180-2

  • Online ISBN: 978-3-642-79178-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation